Healthcare
ImageneBio Appoints Matt Robbins as General Counsel
Brings more than 15 years of corporate, securities, and transactional experience advising public and private life sciences companiesSAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene” or the “Company”), today announced the appointment of Matt Robbins, an experienced life sciences attorney with more than 15 years of corporate, securities, and transactional experience, as General Counsel, effective July 7, 2026. Robbins will oversee Imagene's legal, corporate gove
About this update from Imagenebio, Inc.
Brings more than 15 years of corporate, securities, and transactional experience advising public and private life sciences companies SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, "Imagene" or the "Company"), today announced the appointment of Matt Robbins, an experienced life sciences attorney with more than 15 years of corporate, securities, and transactional experience, as General Counsel, effective July 7, 2026. Robbins will oversee Imagene's legal, corporate governance, intellectual property, and compliance functions, providing strategic counsel as the Company advances its lead candidate, IMG-007. "We are thrilled to welcome Matt to the Imagene management team," said Kristin Yarema, PhD, Chief Executive Officer of Imagene. "Matt's experience building a legal function inside a clinical-stage biotech company, combined with his years advising life science companies through public offerings and complex transactions, is a great fit for Imagene as we continue to advance and scale up our Phase 2 clinical programs in atopic dermatitis and alopecia areata. As we celebrate our one-year company anniversary later this month, we are entering an exciting new phase of growth with important milestones and data readouts on the horizon. Matt's leadership and expertise will be invaluable as we continue to grow, strengthen our organization, and execute on our strategic priorities." Robbins is an experienced corporate and securities attorney whose career spans the life sciences industry in both firm and in-house roles. Most recently, he served as General Counsel of Bright Peak Therapeutics, Inc., a venture-backed clinical-stage biotechnology company, where he built the legal function from the ground up. Prior to Bright Peak, he spent nearly nine years at Cooley LLP in San Diego, advising public and private life sciences companies on corporate, securities, and transactional matters. Earlier in his career, he served as a Senior Consultant at Deloitte & Touche LLP. Robbins holds a JD from Northwestern University Pritzker School of Law and a Bachelor of Arts in Economics from the University of California, Los Angeles. He is admitted to the California State Bar. About ImageneBio, Inc. Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company's program, IMG-007, is a receptor targeting, non-T cell-depleting, ADCC-silenced, anti-OX40 monoclonal antibody with an approximately 5-week half-life. Imagene has completed proof-of-concept clinical trials of IMG-007 in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of IMG-007 in patients with moderate-to-severe atopic dermatitis.